Abstract:Most mammalian antibodies have complementarity determining region (CDR) loops of 8–16 residues, while some human antibodies have longer, protruding CDR loops that play a role in virus neutralization.[1] The bovine antibody repertoire features a subgroup of antibodies with exceptionally long heavy chain complementarity determining region 3 (CDR3H) loops. The lengths of CDR3H in these bovine antibodies range from 40 to 67 amino acid residues.[2] We recently solved the X-ray crystal structure of bovine antibody BLV1H12 which has a CDR3H of 61 residues (Figure 1).[3] The crystal structure revealed a novel CDR3H structure that forms a solvent exposed 2-stranded antiparallel sheet ~20 A (7 amino acids) in length (the stalk region). This β-sheet terminates in a folded protein domain that is stabilized by three pairs of disulfide bonds (the knob region). This knob region was shown to play a critical role in recognition of a viral antigen in the case of one such bovine antibody.[3] Herein we asked whether the knob region of BLV1H12 can be substituted with other native protein and peptide ligands to create chimeric antibodies with new or enhanced properties. For example, such fusion proteins may have improved serum half-lives relative to the native polypeptide,[4] improved binding affinity or specificity due to interactions of the cognate receptor with the other bovine CDRs (or simply through bivalent binding), or improved expression and/or stability in the context of the antibody framework. To begin to explore these possibilities, we first attempted to substitute bovine granulocyte colony-stimulating factor (bGCSF) for the knob region in CDR3H of antibody BLV1H12.[5] The resulting bovine antibody-bGCSF (Ab-bGCSF) fusion protein was stably expressed in mammalian cells, exhibits potency similar to bGCSF in proliferating GCSF-dependent cells, and can significantly increase and sustain neutrophil populations for over three weeks in rodents.

Bovine ultralong CDR-H3 derived knob paratopes elicit potent TNF-α neutralization and enable the generation of novel adalimumab-based antibody architectures with augmented features

Serum albumin binding knob domains engineered within a VH framework III bispecific antibody format and as chimeric peptides

Covalently dimerized Camelidae antihuman TNFa single-domain antibodies expressed in yeast Pichia pastoris show superior neutralizing activity

Novel human single chain antibody design based on the functional epitope of TNF

Overexpression, Effective Renaturation, and Bioactivity of Novel Single-Chain Antibodies Against TNF-α

Functional Antibody CDR3 Fusion Proteins with Enhanced Pharmacological Properties

Optimization and Modification of Anti-Rhtnf-α Single Chain Variable Fragment Antibody: Effective in Vitro Affinity Maturation and Functional Expression of Chimeric Fab.

A Novel TNFα Antagonizing Peptide-Fc Fusion Protein Designed Based on CDRs of TNFα Neutralizing Monoclonal Antibody

Designing and constructing a phage display synthesized single domain antibodies library based on camel VHHs frame for screening and identifying humanized TNF-α-specific nanobody

Overexpression, Effective Renaturation, And Bioactivity Of Novel Single-Chain Antibodies Against Tnf-Alpha

A Novel Domain Antibody Rationally Designed Against TNF-α Using Variable Region of Human Heavy Chain Antibody As Scaffolds to Display Antagonistic Peptides

Rational Design of Humanized Dual-Agonist Antibodies.

Bivalent Llama Single-Domain Antibody Fragments against Tumor Necrosis Factor Have Picomolar Potencies due to Intramolecular Interactions

Humanization of an Anti-Human Tnf-Alpha Antibody by Variable Region Resurfacing with the Aid of Molecular Modeling

A Novel Human Scfv Fragment Against Tnf-Alpha from De Novo Design Method

Reconstruction and Analysis of A Human Small Molecular Antibody to Tumor Necrosis Factor Alpha

Retraction Note To: Structure-based Development and Optimization of Therapy Antibody Drugs Against TNFα

Engineering and Characterization of a Humanized Antibody Targeting TNF-α and RANKL.

Characterization of a novel anti-human TNF-α murine monoclonal antibody with high binding affinity and neutralizing activity

Preparation and Characterization of a Fully Human Monoclonal Antibody Specific for Human Tumor Necrosis Factor Alpha

A Tumor Necrosis Factor (TNF) Receptor-Igg Heavy Chain Chimeric Protein As a Bivalent Antagonist of TNF Activity.